Skip to main content

27-10-2023 | Colorectal Cancer | Editor's Choice | News

ESMO 2023

PFS gain with sotorasib plus panitumumab in refractory KRAS G12C-mutated CRC

Author: Dr. Shreeya Nanda

medwireNews: The CodeBreaK 300 trial points to a significant progression-free survival (PFS) advantage with the use of sotorasib plus panitumumab versus standard of care in patients with chemorefractory metastatic colorectal cancer (CRC) harboring a KRAS G12C mutation.

Related topics